SecBot SecBot
PRESS-RELEASE ·Filed May 18, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed including at the maximum dose. This de-risks the safety profile of TLX101-Tx as it advances alongside the pivotal Phase 3 IPAX BrIGHT trial in recurrent GBM, but the readout is early-stage safety data with no efficacy results.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.17
T+0 close · May 18, 2026 · via day close
Latest settled
+21.24%
T+60 · $12.33
Vs SPY
+14.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $10.17entry
  2. T+1 · 6mo ago +1.08%α +0.04% · $10.28
  3. T+5 · 6mo ago −4.23%α −6.52% · $9.74
  4. T+20 · 5mo ago −2.26%α −3.25% · $9.94
  5. T+60 · 3mo ago +21.24%α +14.95% · $12.33

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed including at the maximum dose. This de-risks the safety profile of TLX101-Tx as it advances alongside the pivotal Phase 3 IPAX BrIGHT trial in recurrent GBM, but the readout is early-stage safety data with no efficacy results.

Key Facts

  • IPAX-2 Phase 1 study (TLX101-Tx in newly diagnosed GBM) completed enrollment of 12 patients across 3 cohorts.
  • No dose-limiting toxicities (DLTs) observed, including at the maximum administered dose of 10 GBq (two 5 GBq doses).
  • ,
  • ],

Financial Impact

Not specified

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3297047

Track record

27 reports on TLX

Performance horizon

9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026